Data / Drug companies / Ajenat Pharmaceuticals LLC
Ajenat Pharmaceuticals LLC: 15 products in the FDA NDC directory, labeler code 82983
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Ajenat Pharmaceuticals LLC (labeler code 82983) lists 15 products in the FDA National Drug Code Directory, covering 10 finished drugs by generic name. By type: 15 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 14, 2026.
The request: Watch Ajenat Pharmaceuticals LLC (FDA labeler code 82983): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 82983
- Products in commercial distribution
- 15
- Packages
- 16
- Finished drugs by generic name
- 10
- Prescription products
- 15
- Over the counter products
- 0
- Controlled substance products
- Schedule III 2, Schedule IV 1, Schedule V 1
- Flagged as original packager
- 12 of 12 products that carry the flag
- Started marketing in the last 12 months
- 7
- Earliest marketing start
- January 31, 2023
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 13 | 86.7% |
| Other unapproved drugs | 1 | 6.7% |
| New drug applications (NDA) | 1 | 6.7% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 15 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Tacrolimus | 3 | 35 |
| Testosterone cypionate | 2 | 24 |
| Glatiramer acetate | 2 | 8 |
| Potassium chloride | 2 | 84 |
| Phenobarbital oral | 1 | 4 |
| Gabapentin | 1 | 91 |
| Potassium chloride for oral solution | 1 | 3 |
| Lacosamide | 1 | 57 |
| Alcohol | 1 | 293 |
| Glycopyrrolate | 1 | 64 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Solution | 6 | 40% |
| Injection, solution | 5 | 33.3% |
| Capsule | 3 | 20% |
| Powder, for solution | 1 | 6.7% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Calcineurin Inhibitor Immunosuppressant | 3 |
| Osmotic Laxative | 3 |
| Potassium Salt | 3 |
| Androgen | 2 |
| Anticholinergic | 1 |
| Cholinergic Muscarinic Antagonist | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Testosterone cypionate | 82983-425 | Injection, solution | Generic drugs (ANDA) | September 14, 2026 |
| Testosterone cypionate | 82983-424 | Injection, solution | Generic drugs (ANDA) | September 14, 2026 |
| Potassium Chloride | 82983-412 | Solution | Generic drugs (ANDA) | March 23, 2026 |
| Potassium Chloride | 82983-411 | Solution | Generic drugs (ANDA) | March 23, 2026 |
| Glatiramer Acetate | 82983-430 | Injection, solution | Generic drugs (ANDA) | March 20, 2026 |
| Glatiramer Acetate | 82983-429 | Injection, solution | Generic drugs (ANDA) | March 20, 2026 |
| Glycopyrrolate Oral Solution | 82983-428 | Solution | Generic drugs (ANDA) | December 12, 2025 |
| Phenobarbital Oral Solution | 82983-417 | Solution | Other unapproved drugs | November 5, 2025 |
| Dehydrated Alcohol | 82983-426 | Injection, solution | New drug applications (NDA) | August 15, 2025 |
| Gabapentin | 82983-423 | Solution | Generic drugs (ANDA) | August 6, 2025 |
| Lacosamide Oral Solution | 82983-427 | Solution | Generic drugs (ANDA) | July 14, 2025 |
| Potassium Chloride for Oral Solution | 82983-403 | Powder, for solution | Generic drugs (ANDA) | March 1, 2023 |
| Tacrolimus | 82983-402 | Capsule | Generic drugs (ANDA) | January 31, 2023 |
| Tacrolimus | 82983-401 | Capsule | Generic drugs (ANDA) | January 31, 2023 |
| Tacrolimus | 82983-400 | Capsule | Generic drugs (ANDA) | January 31, 2023 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.